Aspira Women’s Health Inc. to Report Fourth Quarter and Full Year 2020 Financial Results

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its financial results for Q4 and full year 2020 on March 25, 2021, after market close. An investor conference call and webcast is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative testing options in women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its FDA-cleared products OVA1® and OVERA® assist in evaluating ovarian malignancy risk. Aspira is committed to improving gynecologic health outcomes and addressing ethnic disparities in healthcare.

Positive

• Focus on innovative women's health testing solutions.
• FDA-cleared products for ovarian cancer risk assessment.

Negative

• None.

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the fourth quarter and full year ended December 31^st, 2020, on Thursday, March 25^th, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, March 25th at 4:30 pm ET
Domestic:	877-407-4018
International:	201-689-8471
Conference ID:	13717832
Webcast:	http://public.viavid.com/index.php?id=144003

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

FAQ

When will Aspira Women’s Health report its financial results?

Aspira Women’s Health will report its financial results for Q4 and the full year 2020 on March 25, 2021, after market close.

What time is the investor conference call for Aspira Women’s Health?

The investor conference call for Aspira Women’s Health is scheduled for March 25, 2021, at 4:30 p.m. Eastern Time.

What testing options does Aspira Women’s Health offer?

Aspira Women’s Health offers innovative testing options including OVA1® and OVERA® for ovarian malignancy risk assessment.

What is the stock symbol for Aspira Women’s Health?

The stock symbol for Aspira Women’s Health is AWH.